Clinical trial coverage on Peptide News Digest pulls in Phase 1 through Phase 3 readouts across the peptide universe — GLP-1 obesity and cardiometabolic trials (SELECT, SURMOUNT-4, ACHIEVE-3, REDEFINE-1, SYNCHRONIZE-1), peptide vaccine work (AMPLIFY-201, MEL39), peptide-drug conjugate trials, and antimicrobial peptide programs.
Most of the noise sits with Lilly and Novo, but the interesting reads are usually elsewhere: Bicycle Therapeutics on solid tumors, Lirum on Ewing sarcoma, Cerapedics on lumbar fusion, Pelage on hair loss. Real-world evidence and registry data also land here when they reframe what the randomized trials showed.
Each entry names the sponsor, the phase, and the endpoint. Browse the latest below, or jump to the readouts by drug at #semaglutide, #tirzepatide, or #orforglipron.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
Cytokinetics (NASDAQ: CYTK) presented Saturday August 29, 2026 additional results from the Phase 3 ACACIA-HCM (Myqorzo aficamten for non-obstructive HCM) and MAPLE-HCM trials in a Late-Breaking Clinical Trial Session at ESC Congress 2026 Munich, with simultaneous publications in Circulation and Journal of the American College of Cardiology: Heart Failure. The ACACIA-HCM additional analyses examined improvements in cardiac structure and diastolic function in patients with non-obstructive HCM (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), extending the primary readout (KCCQ Clinical Summary Score and peak VO2) presented in the Hot Line Session Friday August 28 and simultaneously published in NEJM. The follow-up data strengthens the aficamten commercial case for supplemental NDA in Q4 2026 and continues to differentiate the cardiac myosin inhibitor mechanism from mavacamten (Camzyos, Bristol Myers Squibb) which is currently approved only for obstructive HCM.
Alnylam Pharmaceuticals (NASDAQ: ALNY) presented Saturday August 29 and Sunday August 30, 2026 late-breaking prespecified subgroup analyses from the Phase 3 HELIOS-B trial of vutrisiran (AMVUTTRA, an RNAi therapeutic targeting transthyretin for transthyretin amyloidosis with cardiomyopathy, ATTR-CM) at ESC Congress 2026 Munich. Vutrisiran demonstrated consistent clinical benefit across all-cause mortality and recurrent cardiovascular events in patients with or without background tafamidis (the transthyretin tetramer stabilizer marketed as Vyndaqel/Vyndamax by Pfizer). The HELIOS-B trial had documented 28.2% reduction in all-cause mortality and 32.8% reduction in cardiovascular events with vutrisiran plus stabilizer. Additional analyses examined healthy aging, functional capacity, safety, and outcomes by sex. Alnylam also presented Amylo'ExTTRa, a large real-world analysis from the French National Health Data System characterizing the multisystem burden of ATTR-CM beyond cardiac manifestations. Vutrisiran anchors Alnylam's ATTR franchise alongside inclisiran (Leqvio, licensed to Novartis for hypercholesterolemia) and zilebesiran (Phase 3 ZENITH trial in hypertension).
The Factor XIa inhibitor milvexian (an oral small-molecule antithrombotic co-developed by Bristol Myers Squibb (NYSE: BMY) and Janssen) failed to reduce major adverse cardiovascular events versus placebo when added to standard antiplatelet therapy after recent acute coronary syndrome (ACS) in the Phase 3 LIBREXIA ACS trial presented in a Hot Line Session at ESC Congress 2026 Saturday August 29. The primary endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 5.4% of the milvexian arm versus 5.1% on placebo. Researchers observed no differences in intracranial or fatal bleeding between arms, addressing safety concerns that have historically constrained anticoagulant use in the post-ACS setting. The LIBREXIA program continues to assess milvexian in stroke and atrial fibrillation. The Factor XIa class as a whole (also including Bayer-Janssen's asundexian and Anthos Therapeutics' abelacimab) has struggled to demonstrate clean cardiovascular benefit at low bleeding cost.
The STAREE trial (a double-blind Australian primary-prevention trial in adults 70 and older) presented Saturday August 29, 2026 at ESC Congress 2026 Munich and simultaneously published in NEJM showed atorvastatin 40 mg daily reduced major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization) by approximately 30% versus placebo over 5.9 years median follow-up in 9,971 participants (mean age 74.7, 52% women). The co-primary endpoint of disability-free survival (survival free of dementia and physical disability) did not reach statistical significance. Muscle, liver, and diabetes-related adverse events were more common on atorvastatin, though serious adverse events were balanced. STAREE addresses a long-standing evidence gap on statin efficacy in older adults without known cardiovascular disease, diabetes, or dementia. Not a peptide, but the trial matters for peptide-industry readers because it reframes the primary-prevention benefit-risk calculus that will need to be modeled for cardiovascular outcome trials of peptide obesity therapies in older populations.
Cytokinetics (NASDAQ: CYTK) presented Friday August 28, 2026 the full results from the Phase 3 ACACIA-HCM trial of Myqorzo (aficamten, a next-generation cardiac myosin inhibitor) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026 in Munich, Germany, with simultaneous publication in The New England Journal of Medicine. The trial met both dual primary endpoints with statistically significant improvements from baseline to Week 36 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and peak oxygen uptake (peak VO2) versus placebo, plus improvements on key secondary endpoints. LVEF <50% occurred in 10% of aficamten patients vs 1% on placebo, with rare treatment interruptions due to LVEF <40% and two serious heart failure adverse events associated with LVEF <50%. Cytokinetics plans to submit a Supplemental New Drug Application in Q4 2026. There are no currently-approved therapies for non-obstructive HCM, and the ACACIA readout positions aficamten as the potential first-in-class treatment for this indication after the July 2026 initial obstructive-HCM approval.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented updated Phase 1/2a data on ARO-INHBE (an RNA interference therapeutic targeting Activin E) and ARO-ALK7 (RNAi targeting ALK7 receptor) at EASL 2026. Standalone data: ARO-INHBE monotherapy achieved mean visceral fat reduction of -9.9% at week 16 after a single dose and -15.6% placebo-adjusted after two doses at week 24, with a single dose increasing lean muscle tissue by 3.6%; ARO-ALK7 monotherapy achieved -14.1% placebo-adjusted visceral fat reduction at week 8 after a single dose. Combination data: ARO-INHBE plus low-dose tirzepatide (5 mg) enhanced reductions in visceral adipose tissue and liver fat content versus tirzepatide alone in participants with obesity with or without type 2 diabetes. Mean maximum Activin E reduction reached 85.3% at the 400 mg dose with persistent effect beyond 3 months. Additional 2026 readouts expected. The data extend the case for RNAi as a non-peptide, quarterly-dosed obesity add-on capable of shifting body composition rather than just body weight.
Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced Wednesday August 19, 2026 that the Phase 3 INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157, an individualized neoantigen therapy) plus pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in adults with high-risk (Stage IIB-IV) resected cutaneous melanoma compared to Keytruda alone. Mechanism: intismeran autogene is a personalized mRNA therapy that encodes up to 34 tumor-specific neoantigen peptides selected from the individual patient's tumor mutation signature. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The Phase 3 readout is the first positive Phase 3 for an individualized neoantigen therapy and the first Phase 3 to demonstrate substantial improvement over Keytruda alone in the adjuvant melanoma setting. Trial design: randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 evaluating safety and efficacy of the combination versus Keytruda alone. Phase 2b KEYNOTE-942 five-year follow-up data presented at the 2026 ASCO Annual Meeting had shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death for the combination versus Keytruda alone, and the Phase 3 readout confirms and extends those benefits. The result validates the personalized neoantigen mRNA vaccine platform and opens a substantial commercial pathway for the Merck-Moderna collaboration in adjuvant oncology settings beyond melanoma including non-small-cell lung cancer, renal cell carcinoma, and cutaneous squamous cell carcinoma where INTerpath studies are ongoing.
The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.
Vivani Medical (NASDAQ: VANI) continues to progress its long-acting NanoPortal peptide-implant program with two assets in active development. NPM-115 (exenatide implant using NanoPortal technology): LIBERATE-1 first-in-human Phase 1 clinical study completed with a positive safety and tolerability profile plus encouraging performance data on exenatide release from the implant. NPM-139 (novel semaglutide implant): ongoing preclinical study has documented greater than 20% sham-adjusted weight loss for a full year from a single implant administration, with sustained semaglutide exposures documented over 231+ days. Recent preclinical readouts showed sustained semaglutide exposures and greater than 20% sham-adjusted weight loss with a single implant. Phase 1 clinical study initiation for NPM-139 is targeted for H1 2026 pending regulatory clearance. Phase 2 study design is anticipated as a randomized, placebo-controlled, dose-ranging investigation over 4 to 6 months to evaluate weight management in overweight or obese subjects. The long-acting implant delivery format addresses a substantial adherence-and-convenience gap in the current GLP-1 obesity drug class: weekly self-injection adherence in real-world claims data shows 30+ day dose gaps in a substantial share of patients within 12 months, and once-yearly implant dosing would materially change the adherence trajectory. Vivani's NanoPortal platform uses a micron-scale drug reservoir to release peptide payload at zero-order kinetics over extended durations. The category is early-stage but attracts increasing attention as GLP-1 franchise economics push toward longer-acting formats.
Chinese biotech GLP-1 pipeline activity added depth across the week. Minwei Bio's MWN105 registered two clinical trials on August 19-20, 2026: Phase Ib (CTR20253330) targeting semaglutide-intolerant populations (patients unable to reach target Wegovy or Ozempic doses due to GI side effects, roughly 5-10% of real-world users), and Phase II (CTR20253336) covering non-diabetic overweight and obese patients (BMI ≥30 or BMI 27-30 with weight-related comorbidities). Innovent Biologics IBI3032 received FDA IND clearance August 5, 2026 for a US Phase 1 study, and on August 22 a Chinese CTR registration (CTR20253396) was activated for synchronized dual-region development. The Chinese biotech GLP-1 pipeline continues to expand across multiple programs including Hengrui-Kailera's ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), Innovent's mazdutide (GLP-1/glucagon dual agonist in late-stage Chinese and US trials), and multiple novel candidates targeting differentiated patient populations. The semaglutide-intolerant population is a real gap in the current commercial landscape: patients who cannot tolerate GI side effects at 1.7 mg or 2.4 mg semaglutide often plateau at sub-therapeutic doses. A drug specifically designed for that population would address an under-served segment. The dual-region synchronized development pattern (China IND filings + US CTR / FDA IND filings in parallel) reflects Chinese biotechs' increasing sophistication at multi-market clinical strategy.
The Amylyx pipeline follow-on AMX0318, a novel long-acting GLP-1 receptor antagonist development candidate identified in collaboration with Danish peptide discovery specialist Gubra A/S (nominated January 2026), is progressing through Investigational New Drug (IND)-enabling studies with an IND filing targeted for 2027. Development context: AMX0318 was selected as a development candidate after demonstrating a favorable pharmacokinetic profile that may support long-acting administration (extending beyond avexitide's once-daily subcutaneous injection format), strong chemical stability, high in vitro potency, evidence of in vivo activity and tolerability, and high solubility. The Gubra A/S collaboration draws on Gubra's peptide discovery platform (which has also contributed to Boehringer Ingelheim's survodutide dual GLP-1/glucagon agonist for obesity) combined with Amylyx's expertise in GLP-1 receptor antagonist biology developed through the avexitide program. The follow-on candidate extends Amylyx's franchise beyond avexitide into a longer-duration product format that could address post-bariatric hypoglycemia (potentially with weekly or longer dosing) and additional rare diseases where excessive endogenous GLP-1 signaling drives disease. The long-acting profile could substantially improve adherence and quality of life for patients compared to daily subcutaneous injection, and the IND filing in 2027 would position Amylyx to begin Phase 1 human studies as avexitide is entering commercial launch.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced Monday evening August 18, 2026 that the registrational Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) met the FDA-agreed-upon primary endpoint with a 55% reduction in the composite rate of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events versus placebo (p=0.000003). The trial enrolled 78 participants with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to avexitide 90 mg once-daily subcutaneous injection or placebo for 16 weeks across 21 US sites. All secondary endpoints were met: consistent, highly statistically significant, and clinically substantial reductions in Level 2 events by self-monitoring of blood glucose (SMBG), Level 2 events by continuous glucose monitoring (CGM), and Level 3 hypoglycemic events. Avexitide was generally well-tolerated with a favorable safety profile. Mechanism: avexitide is exendin (9-39), a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in the reconfigured gastrointestinal anatomy after Roux-en-Y gastric bypass. Amylyx plans to submit a New Drug Application (NDA) to the FDA by end of 2026 with potential commercial launch in 2027 if approved. If approved, avexitide would be the first FDA-approved therapy for post-bariatric hypoglycemia (which has no currently approved drug therapy) and the first Phase 3 success for a GLP-1 receptor antagonist mechanism (the mechanistic opposite of the semaglutide/tirzepatide agonist class).
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, second only to the 28.7% Lilly reported for TRIUMPH-4 among Phase 3 obesity trials. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.
Structure Therapeutics (NASDAQ: GPCR) reported detailed Phase 2b ACCESS II trial results for aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist for obesity). Key efficacy: 16.3% placebo-adjusted mean weight loss at the 180 mg dose (39 lbs) and 16.0% weight loss at the 240 mg dose (37 lbs) at 44 weeks. This positions aleniglipron as the highest-efficacy oral GLP-1 agonist data reported to date, above Eli Lilly's orforglipron (Foundayo, 7.5-11.2% at 72 weeks in ATTAIN-1) and Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, 13.6% at 64 weeks in OASIS 4). The core Phase 2b ACCESS study had documented 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks. The ACCESS Open-Label Extension (OLE) study documented continued weight loss from 36 weeks up to 16.2% (40.5 lbs) with 120 mg at 56 weeks with no observed plateau, an important tolerability and durability signal. Tolerability profile is consistent with the GLP-1 receptor agonist class with only 3.7% adverse-event-related treatment discontinuation across all active arms in participants who reached 120 mg or higher from weeks 28 to 44. Phase 3 initiation is expected in H2 2026. Aleniglipron is a non-peptide small molecule that binds the GLP-1 receptor, similar to Lilly's orforglipron but distinct from the peptide-based semaglutide and tirzepatide; the small-molecule format provides manufacturing scalability advantages over peptide APIs.
Eli Lilly (NYSE: LLY) plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist peptide) to the FDA in Q1 2027 following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 readouts. TRIUMPH-2 (obesity and type 2 diabetes) enrolled 1,152 adults and documented up to 20.8% mean weight loss and 1.6 percentage point HbA1c reduction at 80 weeks. TRIUMPH-3 confirmed similar efficacy profiles across an additional patient population. Combined with the earlier readouts (TRIUMPH-1 in obesity without diabetes at 28.3% mean weight loss at 80 weeks at the 12 mg dose, and TRIUMPH-4 in obesity plus knee osteoarthritis at 28.7% weight loss with 75.8% reduction in WOMAC pain scores), the retatrutide package now covers four major indication frames with consistent efficacy. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. Potential FDA approval is expected in 2027-2028, positioning retatrutide to set the new weight-loss ceiling in the obesity drug class at up to 28.7% in TRIUMPH-4 and 28.3% in TRIUMPH-1 (versus tirzepatide's 25.5% and semaglutide's 15% in the current approved landscape).
Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.3% mean weight loss at 80 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.
Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026. Trial status: the last participant completed the final study visit in the 16-week double-blind period. Trial design: 78 patients with post-bariatric hypoglycemia (PBH) enrolled across 21 US sites and randomized 3:2 to avexitide 90 mg subcutaneous once daily or placebo for 16 weeks. Primary endpoint (agreed with the FDA): reduction in the composite of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events through Week 16. The trial design was informed by data from five prior clinical trials of avexitide in post-bariatric hypoglycemia that consistently showed statistically significant reductions in Level 2 and Level 3 hypoglycemic events. Avexitide is exendin (9-39), a peptide GLP-1 receptor antagonist that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in patients following Roux-en-Y gastric bypass surgery. If positive, commercial launch of avexitide is anticipated in 2027 for the indication that has no currently approved drug therapy. LUCIDITY is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism.